Literature DB >> 16914603

Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin?

Ilse Mertens1, Robert V Considine, Marc Van der Planken, Luc F Van Gaal.   

Abstract

OBJECTIVE: Leptin has been associated with disturbances in hemostasis and fibrinolysis, with inconsistent results on the influence of fat mass. However, the influence of the amount of visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (SAT) has not yet been studied. In this study, we investigated the relationship between leptin and fibrinogen, von Willebrand factor antigen (vWF:Ag), and plasminogen-activator inhibitor-1 (PAI-1) activity and determined the influence of associated metabolic variables and VAT versus SAT.
METHODS: Fibrinogen, vWF:Ag, PAI-1,VAT and SAT (CT-scan), and insulin resistance (homeostasis model assessment; HOMA-IR) were measured in 199 women and 81 men with overweight or obesity visiting the weight management clinic of a university hospital.
RESULTS: Leptin did not relate to fibrinogen (r = 0.11 and 0.13 in women and men respectively; P > 0.05), a relationship with vWF:Ag was only found in men (r = 0.31; P = 0.005), while leptin related to PAI-1 activity in both men (r = 0.36; P < 0.001) and women (r = 0.23; P < 0.001). Further analysis showed leptin to have an effect on the variation of PAI-1 independent of VAT and HOMA-IR in women, but not in men. Multiple regression showed HOMA-IR to be the most important determinant of PAI-1, both in men and women, but leptin also showed an independent effect. As for vWF:Ag, leptin was an independent determinant in men only.
CONCLUSIONS: PAI-1 related to leptin levels independent of fat mass percentage, HOMA-IR, and the amount of VAT and SAT. For vWF:Ag this relationship was found only in men, and not in women, while a relationship with fibrinogen could not be demonstrated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914603     DOI: 10.1530/eje.1.02239

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Effects of leptin on cardiovascular physiology.

Authors:  Johnathan D Tune; Robert V Considine
Journal:  J Am Soc Hypertens       Date:  2007 Jul-Aug

2.  Leptin links with plasminogen activator inhibitor-1 in human obesity: the SABPA study.

Authors:  Chiné Pieterse; Rudolph Schutte; Aletta E Schutte
Journal:  Hypertens Res       Date:  2015-03-05       Impact factor: 3.872

3.  Coagulation Profile in Patients with Different Etiologies for Cushing Syndrome: A Prospective Observational Study.

Authors:  Amit Tirosh; Maya Lodish; Charalampos Lyssikatos; Elena Belyavskaya; Richard A Feelders; Constantine A Stratakis
Journal:  Horm Metab Res       Date:  2017-02-22       Impact factor: 2.936

4.  Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells.

Authors:  Prachi Singh; Timothy E Peterson; Kara R Barber; Fatima Sert Kuniyoshi; Andrus Jensen; Michal Hoffmann; Abu S M Shamsuzzaman; Virend K Somers
Journal:  Biochem Biophys Res Commun       Date:  2010-01-05       Impact factor: 3.575

5.  Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers.

Authors:  Darko Kastelan; Tina Dusek; Ivana Kraljevic; Ozren Polasek; Zlatko Giljevic; Mirsala Solak; Silva Zupancic Salek; Jozo Jelcic; Izet Aganovic; Mirko Korsic
Journal:  Endocrine       Date:  2009-04-21       Impact factor: 3.633

6.  Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile.

Authors:  S Koutroumpi; V Daidone; M T Sartori; M G Cattini; N M Albiger; G Occhi; S Ferasin; A Frigo; F Mantero; A Casonato; C Scaroni
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.